Sonoma Pharmaceuticals Announces U.S. Commercialization of Loyon® for Relief of Scaling, Burning and Itching Associated with...
October 03 2017 - 4:05AM
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a
specialty pharmaceutical company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care, today announced the U.S.
commercialization of the company’s new Loyon® product. Under
the supervision of a healthcare practitioner, Loyon is intended to
manage and relieve the scaling, erythema, and itching associated
with various types of dermatoses including seborrhea and seborrheic
dermatitis.
Loyon is a unique and patented combination of the dry emollient
Cetiol® CC and the medical silicone oil dimethicone. The liquid
compound is very easily applied, absorbs quickly and spreads
exceptionally well due to its low surface tension. The product
received a new 510(k) clearance from the U.S. Food and Drug
Administration in March 2017.
“Chronic inflammatory skin diseases are commonly characterized
by well-defined areas of erythematous plaques and scales. It
is estimated that 25% of the general population has seborrheic
dermatitis and up to 8.5% have psoriasis with the presence of
scaling. Many patients can feel stigmatized and suffer from marked
physical and psychological disease burden, contributing to
significant reduction of quality of life,” says Dr. Arnd Jacobi,
M.D. and assistant professor at the University Medical Center
Hamburg-Eppendorf, Germany. “Providing a fast and effective
treatment that will help improve the scaling can only help with
this burden and enhance the overall treatment outcome.”
Sonoma Pharmaceutical’s dermatology division 30-person sales
team is currently introducing Loyon to U.S. dermatologists. For
more information phone (855) 317-1107 or visit
www.intraderm.com.
“Loyon has demonstrated an impressive level of efficacy in the
management of scale and itch in multiple dermatoses since first
being commercialized in Europe,” said Sonoma
Pharmaceuticals. “Nearly a quarter of the U.S. population is
afflicted with seborrheic dermatitis and we believe Loyon will
provide these practitioners with a novel tool to help alleviate the
scaling associated with these patients.”
About Global Dermatology MarketAccording to BCC
Research, skin conditions are among the most common health problems
among most national populations, collectively exceeding the
prevalence of conditions such as obesity, hypertension and cancer.
The considerable costs of skin diseases include physician visits,
hospital care, prescription drugs and over-the-counter products for
treating or managing these conditions, as well as indirect costs
due to productivity losses.
The global market for skin disease treatment technologies, which
reached $17.1 billion in 2015, should reach $20.4 billion in 2020,
demonstrating a five-year compound annual growth rate (CAGR) of
3.6%. The U.S market for skin disease treatment, which dominates
the global market throughout the period, totaled $7.5 billion in
2015 and should reach $8.6 billion in 2020, reflecting a five-year
CAGR of 2.6%.
About Sonoma Pharmaceuticals, Inc.Sonoma is a
specialty pharmaceutical company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care. The company’s
products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring
and harmful inflammatory responses. The company's headquarters are
in Petaluma, California, with manufacturing operations in the
United States and Latin America. European marketing and sales
are headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com.
Forward-Looking StatementsExcept for historical
information herein, matters set forth in this press release
are forward-looking within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995,
including statements about the commercial and technology progress
and future financial performance of Sonoma Pharmaceuticals,
Inc. and its subsidiaries (the “Company”). These forward-looking
statements are identified by the use of words such as “believe,”
“achieve,” and “strive,” among others. Forward-looking statements
in this press release are subject to certain risks and
uncertainties inherent in the Company’s business that could cause
actual results to vary, including such risks
that regulatory clinical and guideline developments may
change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances
or approvals, clinical results may not be replicated in actual
patient settings, protection offered by the
Company’s patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available
market for the Company’s products will not be as
large as expected, the Company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to fund further development and clinical studies,
as well as uncertainties relative to varying product formulations
and a multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the Company’s filings with the Securities and
Exchange Commission. The Company disclaims any obligation to update
these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™, IntraDerm Pharmaceuticals™ and
Microcyn® Technology are trademarks or registered trademarks of
Sonoma Pharmaceuticals, Inc. All other trademarks and service marks
are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Dan McFaddenVP of Public and Investor Relations(425)
753-2105dmcfadden@sonomapharma.com
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Apr 2023 to Apr 2024